\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ complaints\\ and\\ no\\ laboratory\\ abnormalities\\.\ \(0\)\
\-\ no\\ specific\\ treatment\\ was\\ undertaken\\,\\ as\\ the\\ patient\\ was\\ asymptomatic\\ and\\ this\\ was\\ considered\\ an\\ incidental\\ finding\\.\ \(0\)\
\-\ small\\ focal\\ area\\ of\\ thickening\\ in\\ the\\ non\\-dependent\\ portion\\ of\\ the\\ gallbladder\\ wall\\ with\\ a\\ bright\\ echogenic\\ focus\\ and\\ a\\ distal\\ comet\\-tail\\ artifact\\.\ \(0\)\
\-\ adenomyomatosis\ \(9\)\
\-\ focal\\ gallbladder\\ wall\\ thickening\\:\ \(0\)\
\-\ \\â\\€\\¢benign\\ conditions\ \(0\)\
\-\ \\Â\\»adenomyomatosis\ \(0\)\
\-\ \\Â\\»polyps\ \(0\)\
\-\ \\Â\\»other\\ benign\\ tumors\\ \\(adenoma\\,\\ cystadenoma\\)\ \(0\)\
\-\ \\â\\€\\¢malignancy\ \(0\)\
\-\ \\Â\\»gallbladder\\ adenocarcinoma\ \(0\)\
\-\ \\Â\\»cholangiocarcinoma\ \(1\)\
\-\ \\Â\\»hepatocellular\\ carcinoma\ \(1\)\
\-\ \\Â\\»metastatic\\ cancer\ \(1\)\
\-\ 61\\ yo\\ african\\ american\\ male\\ presenting\\ for\\ follow\\-up\\ evaluation\\ of\\ portal\\ hypertension\\.\ \(0\)\
\-\ comet\\ tail\\ artifact\\ is\\ caused\\ by\\ reverberation\\ of\\ the\\ ultrasound\\ beam\\ off\\ cholesterol\\ crystals\\ trapped\\ within\\ rokitansky\\-aschoff\\ sinused\\ in\\ the\\ gallbladder\\ wall\\.\\ \\ it\\ is\\ highly\\ specfic\\ for\\ adenomyomatosis\\ and\\ confirmed\\ the\\ diagnosis\\ in\\ this\\ case\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\Â\\»\\:\\ 0\\.22159727568307402\ \(0\)\
\-\ adenomyomatosis\\:\\ 0\\.14099027969560063\ \(0\)\
\-\ gallbladder\\:\\ 0\\.12348836759862147\ \(0\)\
\-\ artifact\\:\\ 0\\.06825341811955553\ \(0\)\
\-\ \\â\\€\\¢benign\\:\\ 0\\.06628209341328194\ \(0\)\
\-\ \\â\\€\\¢malignancy\\:\\ 0\\.06628209341328194\ \(0\)\
\-\ sinused\\:\\ 0\\.06628209341328194\ \(0\)\
\-\ specfic\\:\\ 0\\.06628209341328194\ \(0\)\
\-\ reverberation\\:\\ 0\\.061070460476740994\ \(0\)\
\-\ rokitansky\\-aschoff\\:\\ 0\\.061070460476740994\ \(0\)\
\-\ non\\-dependent\\:\\ 0\\.058021850641341265\ \(0\)\
\-\ wall\\:\\ 0\\.055830656847490515\ \(0\)\
\-\ comet\\-tail\\:\\ 0\\.0541810564776872\ \(0\)\
\-\ comet\\:\\ 0\\.05064719460365911\ \(0\)\
\-\ undertaken\\:\\ 0\\.046439557100385255\ \(0\)\
\-\ crystals\\:\\ 0\\.046439557100385255\ \(0\)\
\-\ trapped\\:\\ 0\\.046439557100385255\ \(0\)\
\-\ thickening\\:\\ 0\\.04355826420591506\ \(0\)\
\-\ beam\\:\\ 0\\.043390947264985526\ \(0\)\
\-\ cholesterol\\:\\ 0\\.04070918076920558\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.04046264074798009\ \(0\)\
\-\ polyps\\:\\ 0\\.03893182153563994\ \(0\)\
\-\ 61\\:\\ 0\\.03782953977479877\ \(0\)\
\-\ cystadenoma\\:\\ 0\\.03733361520493564\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.03702028666057046\ \(0\)\
\-\ focal\\:\\ 0\\.03669915194193085\ \(0\)\
\-\ tail\\:\\ 0\\.035373267366866065\ \(0\)\
\-\ portal\\:\\ 0\\.03381977677015179\ \(0\)\
\-\ african\\:\\ 0\\.03352488419005193\ \(0\)\
\-\ bright\\:\\ 0\\.032121982268394696\ \(0\)\
\-\ echogenic\\:\\ 0\\.03196368595863656\ \(0\)\
\-\ conditions\\:\\ 0\\.03196368595863656\ \(0\)\
\-\ highly\\:\\ 0\\.030940135775744972\ \(0\)\
\-\ american\\:\\ 0\\.030605911997016903\ \(0\)\
\-\ off\\:\\ 0\\.029344838633311627\ \(0\)\
\-\ focus\\:\\ 0\\.0288630427183904\ \(0\)\
\-\ complaints\\:\\ 0\\.027891525940345243\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.027756048455362697\ \(0\)\
\-\ caused\\:\\ 0\\.026950449677533166\ \(0\)\
\-\ adenoma\\:\\ 0\\.026830784600045204\ \(0\)\
\-\ specific\\:\\ 0\\.026558757106981277\ \(0\)\
\-\ presenting\\:\\ 0\\.02618646338873029\ \(0\)\
\-\ considered\\:\\ 0\\.025936409089809372\ \(0\)\
\-\ hypertension\\:\\ 0\\.025329180844362316\ \(0\)\
\-\ incidental\\:\\ 0\\.024329237578799064\ \(0\)\
\-\ confirmed\\:\\ 0\\.024160899271329302\ \(0\)\
\-\ tumors\\:\\ 0\\.024133205696770684\ \(0\)\
\-\ laboratory\\:\\ 0\\.02367738147258696\ \(0\)\
\-\ abnormalities\\:\\ 0\\.02359973399773095\ \(0\)\
\-\ portion\\:\\ 0\\.023272230431271326\ \(0\)\
\-\ was\\:\\ 0\\.02229197418527113\ \(0\)\
\-\ benign\\:\\ 0\\.02217331103032482\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.021718739834557046\ \(0\)\
\-\ cancer\\:\\ 0\\.02112154334108846\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.020902533770238662\ \(0\)\
\-\ finding\\:\\ 0\\.020707229361191588\ \(0\)\
\-\ area\\:\\ 0\\.020314558226573437\ \(0\)\
\-\ no\\:\\ 0\\.019408514677529368\ \(0\)\
\-\ yo\\:\\ 0\\.019333470100020764\ \(0\)\
\-\ ultrasound\\:\\ 0\\.019061072067716563\ \(0\)\
\-\ evaluation\\:\\ 0\\.018663449592682763\ \(0\)\
\-\ carcinoma\\:\\ 0\\.018209982481322304\ \(0\)\
\-\ distal\\:\\ 0\\.017468260067263357\ \(0\)\
\-\ metastatic\\:\\ 0\\.01617375491440669\ \(0\)\
\-\ other\\:\\ 0\\.014809312396259012\ \(0\)\
\-\ small\\:\\ 0\\.014801317927677582\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0147535288028603\ \(0\)\
\-\ this\\:\\ 0\\.014453191177656135\ \(0\)\
\-\ it\\:\\ 0\\.014442469056639222\ \(0\)\
\-\ case\\:\\ 0\\.014056424307272712\ \(0\)\
\-\ treatment\\:\\ 0\\.013004638793991632\ \(0\)\
\-\ within\\:\\ 0\\.012256627130722418\ \(0\)\
\-\ male\\:\\ 0\\.011618086751033633\ \(0\)\
\-\ for\\:\\ 0\\.010964032310416767\ \(0\)\
\-\ by\\:\\ 0\\.010698277468006577\ \(0\)\
\-\ as\\:\\ 0\\.009718627863865622\ \(0\)\
\-\ in\\:\\ 0\\.009505200679855373\ \(0\)\
\-\ an\\:\\ 0\\.008884698227704735\ \(0\)\
\-\ \\:\\:\\ 0\\.008498306887147858\ \(0\)\
\-\ is\\:\\ 0\\.00845550042683798\ \(0\)\
\-\ patient\\:\\ 0\\.006440540833957804\ \(0\)\
\-\ the\\:\\ 0\\.006236809836253795\ \(0\)\
\-\ a\\:\\ 0\\.005963906794264681\ \(0\)\
\-\ \\(\\:\\ 0\\.005431291174765868\ \(0\)\
\-\ and\\:\\ 0\\.005413804683675742\ \(0\)\
\-\ \\)\\:\\ 0\\.005364945053483497\ \(0\)\
\-\ \\,\\:\\ 0\\.0040708280528915395\ \(0\)\
\-\ of\\:\\ 0\\.0035038737082101782\ \(0\)\
\-\ \\.\\:\\ 0\\.0016014828314592305\ \(0\)\
\-\ with\\:\\ 0\\.0008797306472924039\ \(0\)\
